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Preoperative chemoradiation currently serves as the standard treatment for locally advanced rectal cancer.1 Patients treated with chemoradias
tion had lower rates of local recurrence and toxicity and 
similar rates of survival compared with patients getting 
postoperative chemoradiation.2 In rectal cancer treats
ment, the most frequently used drug in combination 
with radiation therapy (RT) is 5sfluorouracil (5sFU). 
The most common preoperative chemoradiation regis
mens include 45s50 Gy of pelvic RT plus concurrent 
FU in the first and last week of RT or prolonged cons
tinuous infusion FU for the whole RT course.3,4
In the Intergroup 0144 trial, no significant differencs
es were observed for overall survival (OS) and relapses
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BACKGROUnD: 5-fluorouracil (fu) is commonly used in preoperative chemoradiation in locally advanced 
rectal cancer, but not all patients cooperate in taking the 5-day continuous infusion regimen. raltitrexed (ra), 
a thymidylate synthase inhibitor, is one of the agents used in place of fu in such cases. We retrospectively 
compared the toxicity, tumor downstaging, pathologic response and relapse rate with bolus fu or ra during 
concurrent radiotherapy (rt) to assess the role of ra in place of fu.
PATIEnTS AnD METHODS: We conducted a retrospective analysis of response rates and toxicity data on 59 
patients diagnosed with locally advanced rectal cancer and treated with surgery following preoperative chemo-
radiation with either concurrent fu or ra between January 1999 and december 2004.
RESULTS: median follow-up was 38 months (range, 1-70). ten patients (10%) had grade 3 gastrointestinal (GiS) 
toxicity during chemoradiation. the pathologic complete response rates were 6% with fu and 7% with ra 
(P=0.844), while 66.7% of patients treated with fu and 37.1% with ra had downstaging of the t stage after 
chemoradiation (P=0.026). the sphincter preservation rates were 45.8% with fu and 51.4% with ra (P=0.912). 
the 5-year local control rates were 79.2% for patients treated with rt+fu and 85.76% for patients treated with 
rt+ra (P=0.510). 
COnCLUSIOn: compared with the rt+ra regimen, the incidence of downstaging was greater with rt+fu, 
but rt+fu was associated with a correspondingly greater rate of acute grade 2 GiS toxicity. however, no sig-
nificant differences were seen in sphincter preservation, pathologic complete response, local control and distant 
recurrences rates among patients. fu seems to be the best therapeutic choice, while ra seems to be as effective 
as bolus fu.
free survival (RFS) among different regimens of 5sFUs
based postoperative therapy.5 On the other hand, in the 
trial conducted by O’Connell et al, patients treated with 
postoperative RT with concurrent protracted venous 
infusion 5sFU had significantly greater rates of OS and 
RFS compared with bolus 5sFU.4 Continuous infusion 
has the biological advantage of prolonging the exposure 
of cells to 5sFU and improving antistumor activity. Its 
disadvantages include the need for an indwelling cens
tral venous catheter and infusion pumps, with potential 
risks for complications such as infection, bleeding, ves
nous thrombosis and increases in the treatment cost.6,7 
For this reason, we prefer bolus 5sFU applications 
routinely in our department for chemoradiotherapy 
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in locally advanced rectal cancer. Furthermore, not all 
patients cooperate in taking a 5sday 5sFU treatment. 
In such cases, other fluropyrimidines (capecitabine, 
UFT) or thymidylate synthase inhibitors (raltitrexed) 
are used.
Raltitexed (RA) is a quinazoline folate analog that 
acts as a specific thymidylate synthese inhibitor.8 RA 
polyglutamates on entering cells, resulting in markedly 
enhanced potency and duration and thymidylate syns
thase inhibition, permitting an every 3 week adminiss
tration schedule.9 Similar to 5sFU, RA is a radiation 
sensitizer, both in vitro and in vivo. In vitro studies ass
sessing the radiosensitizing properties of RA demons
strated that this agent affects the shoulder of RT surs
vival curves. In vivo, tumor growth delay was observed 
when RA was administered intermittently with fracs
tionated RT.10 Since RA has a long halfslife (101s270 
hours), it can simulate prolonged FU infusion without 
the use of central venous catheters.7 For this reason, 
preoperative RT for rectal cancer may be delivered with 
concurrent RA. The recommended dose of raltitrexed 
is 3.0 mg/m2.11
The goal of this study was to retrospectively analyze 
toxicity, tumor downstaging, pathologic response and 
relapse rate differences in locally advanced rectal cancer 
patients treated with preoperative RT with concurrent 
5sFU or concurrent RA. 
PATIEnTS AnD METHODS
Between January 1999 and December 2004, 59 patients 
with histologically confirmed rectal adenocarcinoma 
with no evidence of distant metastasis and no previous 
history of pelvic RT and who were treated in our des
partment with preoperative RT and concurrent FU or 
concurrent RA followed by surgery were included. In 
a review of patient files, acute toxicity was graded uss
ing the Radiation Therapy Oncology Group (RTOG) 
Acute Radiation Morbidity Scoring Criteria.
Pretreatment evaluation included a complete history 
and physical examination assessed at baseline by chest 
xsray, abdomen and pelvic CT, MRI, flexible endoscopy. 
Endoscopic ultrasonography (EUS) was performed for 
some patients. Clinical stage was determined based on 
the CT, MR and EUS findings. The American Joint 
Committee on Cancer TNM 2002 system was used 
for staging. The clinical stage was T3 for 17 (71%) and 
T4 for 7 (29%) patients in RT+FU group and T3 for 
28 (80%) and T4 for 7 (20%) patients in the RT+RA 
group. The clinical stage was N0 for 20 (83%) and N+ 
for 4 (17%) patients in the FU group and N0 for 28 
(80%) and N+ for 7 (20%) patients in the RA group.
All patients were treated with preoperative chemoras
diotherapy followed by surgery. Patients were simulated 
in the prone position with parallelsopposed anteroposs
teriorsposteroanterior (APsPA) twosfields technique 
(59%) and posterior and two lateral threesfields techs
nique. Cos60 (72%) and an 18 MV linear accelerator 
(28%) were used. The median radiation dose was 50.4 
Gy (range, 45s52.5). All patients were irradiated to a 
total dose of 45 Gy in 25 fractions in 5 weeks. An ads
ditional boost was given in 83% of patients. 5sFU 425 
mg/m2 and leucovorin (LV) 25 mg/m2 were adminiss
tered for four days in the first week and for three days 
beginning in the fifth week. RA was administered 3mg/
m2 every 3 weeks. Surgery was performed 6 weeks afs
ter completion of chemoradiation. The choice of surgis
cal procedure was either low anterior resection (LAR) 
(56%) or abdominoperineal resection (APR) (44%). In 
addition to concurrent chemotherapy, all patients res
ceived adjuvant therapy of 4 cycles of FU+LV (5 daily 
treatments) every 28 days or 4 cycles of RA every 21 
days.
Patient characteristics, toxicities, downstaging, and 
sphincter preservation were compared between the two 
groups using the Chissquare test, Fisher exact test or 
student t test and Kruskal Wallis test, for which P vals
ues less than 0.05 were considered statistically signifis
cant. All statistical analysis were conducted using SPSS 
(Version 10.0) statistical software.
RESULTS
The median age of the patients was 55 years (range, 26s
80 years). Clinical characteristics are shown in Table 1. 
The worst grades of acute toxicity during chemoradias
tion in each group are shown in Table 2. Patients treats
ed with FU had a greater rate of grade 2 gastrointestinal 
toxicity (diarrhea, rectal pain/tenesmus and mucositis) 
(65.2% and 34.3%, P=0.008). The FU group had a 
greater rate of grade 1 hematologic toxicity, but the RA 
group had a greater rate of grade 2 hematologic toxicity 
(P<0.05). None of the patients required hospitalization 
or dose reduction, discontinuation or other modificas
tion during chemoradiation and chemotherapy.
No significant difference was found in the rate of 
pathologic complete response (Table 3). Tumor downs
staging was determined by comparing pretreatment T 
stage (as defined by clinical, radiographic and ultras
sound staging) and the pathological stage. Although tus
mor downstaging was observed in each group, a signifis
cant difference was found in the rate of downstaging in 
patients treated with RT+FU (66.7%) compared with 
patients treated with RT+RA (37.1%) (P=0.026).
No significant difference was found in the rates 
of sphincter preservation between the two groups 
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Table	1.		patient characteristics.
Characteristics
RT+FU RT+RA
P
n % n %
Gender
male 19 79.2 25 71.4
0.503
Female 5 20.8 10 28.6
median distance (distance of the 
tm site to anal verge [cm]) 6.73 5.97 >0.05
Pre-treatment	hemoglobin	level
8b10 g 1 4.2 6 17.1
0.0433
10b12 g 10 41.7 10 28.6
12b14 g 7 29.2 10 28.6
14b16 g 6 25 9 25.2
Pre-operative	TNM	stage
T3n0m0 15 62.6 22 62.9
0.266
T3n+m0 2 8.3 6 17.2
T4n0m0 5 20.8 6 17.1
T4n+m0 2 8.3 1 2.9
Pathologic	type
adenocarcinoma 22 91.7 31 89
0.585
mucinous adenocarcinoma 2 8.3 4 11
Grade
Well differentiated 1 4.2 6 17.1
0.037moderately differentiated 18 75 28 80
poorly differentiated 5 20.8 1 2.9
rT: radiotherapy, Fu: 5bfluorouracil, ra: raltitrexed
(P=0.9129). Surgery of 11 (45.8%) of the patients treats
ed with RT+FU consisted of sphincterssparing surgery 
methods, including low anterior resection and surgery 
of the 13 patients consisted of abdominoperineal resecs
tion (54.2%). Of the patients treated with RT+RA, 18 
(51.4%) underwent sphincterssparing surgery, includs
ing low anterior resection. The other patients (n=17) 
were treated with abdominoperineal resection (48.6%). 
In addition to acute toxicity of chemoradiotherapy 
postoperative complications such as anastomotic leaks
age did not occur.
The median followsup interval was longer for the 
RT+FU group then the RT+RA group (49 months 
and 29 months, respectively). Five patients (20.8%) 
in the RT+FU group and 5 patients (14.3%) in the 
RT+RA group developed locoregional recurrence. The 
local control rate was 79.2% for patients treated with 
RT+FU and 85.7% for patients treated with RT+RA 
and no significant differences were found between the 
two groups for local control (P=0.510). All local relapss
es occurred in T4 and N+ patients and 18% of the total 
patients had persistent positive lymph nodes following 
chemoradiotherapy and all had relapses. Thirteen pas
tients died due to reasons related to the disease, includs
ing 5 patients (20.8%) in the RT+FU group and 8 pas
tients (22.9%) in the RT+RA group (P=0.679).
DISCUSSIOn
Flourouracil is currently accepted as the standard cys
totoxic agent for preoperative chemoradiotherapy of 
rectal cancer. Because of the disadvantages of continus
ous infusion, there are studies evaluating mainly oral, als
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Table	2.		Grades of acute toxicity during chemoradiotherapy.
Toxicity
RT+FU RT+RA
P
G1 G2 G3 G1 G2 G3
Gastrointestinal
Diarrhea 1 (4.3%) 10 (40.9%) 1 (4.4%) 1 (2.8%) 2 (5.7%) 1 (2.9%)
0.008
rectal pain/tenesmus 2 (8.8%) 2 (8.1%) 2 (8.6%) 1 (2.8%) 6 (17.2) 2 (5.8%)
Oral mucositis 1 (4.3%) 4 (16.2%) 1 (4.4%) 2 (5.8%) 4 (11.4%) 3 (8.4%)
4 (17.4%) 16 (65.2%) 4 (17.4%) 4 (11.4%) 12 (34.3%) 6 (17.1%)
Hematologic
anemia 8 (33.3%) b b 10 (28.6%) 3 (8.6%) b
0.030
leukopenia 8 (33.3%) b b 8 (22.8%) 3 (8.6%) b
Thrombocytopenia 4 (16.7%) b b 2 (5.7%) 2 (5.7%) b
20 (83.3%) b b 20 (57.1%) 8 (22.9%) b
rT: radiotherapy, Fu: 5bfluorouracil, ra: raltitrexed
Table	3.		pathologic response to chemoradiotherapy.
Characteristics
RT+FU RT+RA
P
n % n %
pathologic complete response 4 16.7 3 8.6 0.844
pathologic T stage
<T1 5 20.9 4 11.5
0.844
  T2 6 25 8 12.8
  T3 11 45.8 18 51.4
  T4 2 8.3 5 14.3
Downstaging 16 66.7 13 37.1 0.026
Spinchter preservation 11 45.8 18 51.4 0.912
rT: radiotherapy, Fu: 5bfluorouracil, ra: raltitrexed
ternative agents. Although these studies demonstrated 
no significant difference compared to FU applied either 
continuously or as a bolus, toxicity differences were res
ported. Kim et al12 reported that when capecitabine, as 
one of the alternative agents, was retrospectively coms
pared to bolus FU, capecitabine had a better pathologic 
complete response, and downstaging or sphincter press
ervation rates. On the other hand, another retrospecs
tive trial demonstrated a significant difference only 
for downstaging when capecitabine was compared to 
continuous infusion FU.13 Another retrospective trial 
comparing capecitabine with continuous infusion FU 
showed no significant difference between these two 
agents in toxicity or survival.1
In the first trials reported with RA, including ads
vanced cases, RA results were similar to those with FU14 
so RA is considered an alternative agent to FU. Further 
phase II trials evaluating RA in preoperative chemos
radiotherapy as a single agent or in combination with 
oxaliplatine7,15 showed pathologic complete response 
rates of 24% and 43% and downstaging rates as 42% vs. 
73%. Our study is the first one to compare FU and RA 
retrospectively. Because the study is retrospective, the 
distribution of the two groups is not balanced. While 
wellsdifferentiated cases in the RA arm were high, 
poorly differentiated cases are dominant in the FU arm. 
There were also differences in RT application as the 2s
field technique was used in the FU arm and threesfield 
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was used for RA arm. Despite these disadvantages in 
the FU arm, downstaging is significantly better in that 
arm. In evaluating toxicity results, FU showed higher 
rates of GI toxicity whereas RA had higher rates of 
hematologic toxicity. There was no difference between 
local control. 
The dose of FU in our study regimen (first cycle 
for 4 days instead of 5 and the second cycle for 3 days, 
concomitant with radiotherapy) was a modified form 
of the one used in one of the arms in the Intergroup 
0114 study (FU 425mg/m2+LV 20mg/m2; days 1s5). 
That regimen is accepted as the standard therapy in our 
country.16 Despite use of a higher dose than that sugs
gested by Minsky et al17 (325 mg/m2) and Bosset et al.18 
(350 mg/m2), the amount of grade 3 toxicity (17%) in 
our study was not different from that reported by those 
authors due to the short period of application, yet grade 
2 toxicity (65.2%) was fairly high. The relatively high 
percentage of grade 2 toxicity seen in the FU arm may 
be related to the greater number of patients treated with 
two opposite AP and PA fields as well as the fact that we 
still use cobalt sources. 
Another different outcome in our study was the relas
tively high incidence of local failure rates even if they 
were equal in both arms (20.8% and 14.3%). Local failure 
rates reported in the literature vary in a range of 4% to 
14%. Downstaging is found to be the factor most affects
ing local control and survival when local failure causes 
are thoroughly studied.19,20 The decrease in downstags
ing increases local failure roles. In our study these rates 
were 66.7% and 37.1%, while they are about 80% in the 
literature. The pathologic characteristics of the tumor as 
well as the depth of penetration in the intestinal wall, 
nodal invasion, degree of invasion and invasion of the 
adjacent organs are also considered factors increasing los
cal failure.21 In our study, all local relapses occurred in 
T4 and N+ patients. The local failure rates in T4 pas
tients were 20.8% and 17.1% in the FU and RA arms, 
respectively; the local failure rates in N+ patients were 
16.4% and 20.1% in the FU and RA arms respectively. 
The existence of persisting positive lymph nodes and 
high thymidylate synthase (TS) gene expression follows
ing therapy are other factors increasing local failure.22 
In our research, 18% of the total patients had persistent 
positive lymph nodes following chemoradiotherapy and 
all had relapses.
The number of local failures proportionally increases 
with the tumor volume while pathologic complete res
sponse rates inversely decrease with tumor volume.23 No 
relapses were seen in patient subgroups with complete 
responses (16.7% and 8.7%, in the FU and RA arms, 
respectively) whereas all relapses occurred in other pas
tients. Tumor volume in patients with complete response 
was below 200 cc, which is in concert with data reported 
in the literature. Local failures are primarily caused by 
the pathologic characteristics of the disease rather than 
treatment factors.
The existence of a similar number of pathologic 
complete responses and local failures in both groups 
and excessive gastrointestinal toxicities in the FU arm 
versus excessive hematological toxicities in the RA arm, 
plus better downstaging in the FU arm, denotes that 
RA is not superior to FU. FU still seems to be the best 
therapeutic choice for preoperative chemoradiotherapy 
of rectal cancer while RA appears to be as effective as 
bolus FU.
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